Aequim Alternative Investments LP Reduces Stake in Jazz Pharmaceuticals plc (NASDAQ:JAZZ)

Aequim Alternative Investments LP cut its holdings in shares of Jazz Pharmaceuticals plc (NASDAQ:JAZZ - Free Report) by 35.5% during the 4th quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 16,700 shares of the specialty pharmaceutical company's stock after selling 9,200 shares during the quarter. Aequim Alternative Investments LP's holdings in Jazz Pharmaceuticals were worth $2,057,000 at the end of the most recent quarter.

Other hedge funds have also recently made changes to their positions in the company. Fuller & Thaler Asset Management Inc. boosted its position in Jazz Pharmaceuticals by 117.4% during the 4th quarter. Fuller & Thaler Asset Management Inc. now owns 939,351 shares of the specialty pharmaceutical company's stock valued at $115,681,000 after buying an additional 507,234 shares during the period. Darwin Global Management Ltd. purchased a new stake in shares of Jazz Pharmaceuticals during the fourth quarter worth about $59,668,000. Dimensional Fund Advisors LP boosted its holdings in shares of Jazz Pharmaceuticals by 18.7% during the fourth quarter. Dimensional Fund Advisors LP now owns 2,035,070 shares of the specialty pharmaceutical company's stock worth $250,619,000 after purchasing an additional 320,724 shares during the period. GMT Capital Corp grew its stake in shares of Jazz Pharmaceuticals by 140.0% in the fourth quarter. GMT Capital Corp now owns 508,800 shares of the specialty pharmaceutical company's stock worth $62,659,000 after purchasing an additional 296,800 shares during the last quarter. Finally, Tri Locum Partners LP purchased a new position in Jazz Pharmaceuticals during the 4th quarter valued at about $19,927,000. 89.14% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

A number of equities research analysts have recently weighed in on the company. Barclays reiterated an "overweight" rating and issued a $200.00 price objective (up from $190.00) on shares of Jazz Pharmaceuticals in a research report on Thursday, February 27th. Truist Financial boosted their price objective on shares of Jazz Pharmaceuticals from $220.00 to $230.00 and gave the company a "buy" rating in a research report on Thursday, March 6th. Morgan Stanley restated an "overweight" rating and issued a $183.00 price objective (up from $175.00) on shares of Jazz Pharmaceuticals in a report on Friday, March 7th. Piper Sandler reaffirmed an "overweight" rating and set a $176.00 target price (up previously from $163.00) on shares of Jazz Pharmaceuticals in a research note on Wednesday, February 26th. Finally, Cantor Fitzgerald downgraded shares of Jazz Pharmaceuticals from an "overweight" rating to a "neutral" rating and increased their price target for the stock from $140.00 to $150.00 in a research note on Wednesday, February 26th. One equities research analyst has rated the stock with a hold rating, thirteen have assigned a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of "Buy" and a consensus price target of $187.71.

Insider Buying and Selling

In other Jazz Pharmaceuticals news, EVP Neena M. Patil sold 3,800 shares of Jazz Pharmaceuticals stock in a transaction on Thursday, February 27th. The stock was sold at an average price of $144.87, for a total value of $550,506.00. Following the completion of the sale, the executive vice president now owns 33,318 shares of the company's stock, valued at approximately $4,826,778.66. This trade represents a 10.24 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CEO Bruce C. Cozadd sold 1,000 shares of the company's stock in a transaction on Thursday, May 1st. The shares were sold at an average price of $116.35, for a total value of $116,350.00. Following the transaction, the chief executive officer now directly owns 439,307 shares in the company, valued at approximately $51,113,369.45. The trade was a 0.23 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 28,236 shares of company stock worth $3,956,190 in the last quarter. Corporate insiders own 4.20% of the company's stock.

Jazz Pharmaceuticals Stock Down 1.5 %

Jazz Pharmaceuticals stock traded down $1.86 during mid-day trading on Monday, hitting $118.19. The company had a trading volume of 1,276,961 shares, compared to its average volume of 806,745. Jazz Pharmaceuticals plc has a 12 month low of $95.49 and a 12 month high of $148.06. The company has a market capitalization of $7.28 billion, a PE ratio of 16.65, a price-to-earnings-growth ratio of 1.04 and a beta of 0.42. The stock's 50 day moving average price is $122.63 and its two-hundred day moving average price is $122.52. The company has a current ratio of 4.26, a quick ratio of 3.74 and a debt-to-equity ratio of 1.46.

Jazz Pharmaceuticals Profile

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.